A Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs Interleukin-2 (Primary) ; Peripheral blood lymphocytes-Iovance Biotherapeutics/Ohio State University Comprehensive Cancer Center (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Iovance Biotherapeutics
- 04 Nov 2019 Status changed from planning to recruiting, according to an Iovance Biotherapeutics media release.
- 04 Nov 2019 According to an Iovance Biotherapeutics media release, patient dosing in this study is planned before the end of 2019.
- 04 Nov 2019 According to an Iovance Biotherapeutics media release, the IND application has been accepted by the FDA and this study has been cleared to proceed. This study is currently active at one clinical site.